HOXA5 and breast carcinoma: To corroborate the clinical relevance of the elevated expression of HOXA5 in conferring tamoxifen resistance, we used patient data retrieved from a publicly available gene expression profiling dataset (GSE1379) on 60 paired primary ER+ breast cancer patients and patients with recurrent cancer following tamoxifen monotherapy for 5 years.